The M18/2 antibody reacts with the common β2 chain of LFA-1 (CD11a/CD18, αLβ2 integrin), Mac-1 (CD11b/CD18, αMβ2 integrin), and
gp150, 95 (CD11c/CD18, αXβ2 integrin). Expression of CD18 is limited to leukocytes, where it is widely distributed in consort with the three
integrin α chains (CD11a, CD11b, and CD11c). Among splenocytes, NK cells have the highest density of CD18, and T lymphocytes express a
higher density than the remaining cells. The β2 integrins are important mediators of leukocyte-endothelium interactions. It has been reported
that M18/2 antibody blocks in vivo metastasis of the LB lymphoma to the spleen and that it blocks in vitro formation of aggregates of LB cells
and splenocytes. However, other reports indicate that mAb M18/2 has no effect on CTLmediated killing, adherence of C3bi-sensitized
erythrocytes to Mac-1, antigen-specific binding of T cells to antigen-producing cells, or rejection of cardiac allografts. Recent in vitro studies
indicate that M18/2 antibody stimulates adhesion of Mac-1 to its ligands C3bi and ICAM-1, and it stimulates adhesion of LFA-1 to ICAM-1,
but it has no effect upon the interactions of LFA-1 with ICAM-2 nor ICAM-3.
Alternative antibody clone GAME-46 (Cat. No. 555280) has been reported to block in vitro adhesion of LFA-1-expressing cells to the ligands
ICAM-1, ICAM-2, ICAM-3 and of Mac-1-expressing cells to ICAM-1, C3bi, and fibrinogen.
注意事项：
1.Since applications vary, each investigator should titrate the reagent to obtain optimal results.
2.Store undiluted at 4°C.
京公网安备11010802025653 版权所有：北京逸优科技有限公司
